Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data
Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.
How this was made
The 30-second read
Why it matters
The CHAPTER-3 trial demonstrates an 83% reduction in attack rate, positioning the drug for FDA submission in H1 2027.
Market read
First‑time reporting of pivotal Phase 3 data is a material catalyst for PHVS, likely driving short‑term price action.
What to watch
Cash runway and upcoming NDA filing timeline could limit upside if financing gaps appear.
Background
Pharvaris N.V. focuses on oral bradykinin B2 receptor antagonists for hereditary angioedema.
Ticker impact
Pharvaris reported positive Phase 3 CHAPTER-3 trial results, meeting primary and all secondary endpoints for deucrictibant XR.
upward pressure, potential breakout above recent highs
First disclosure of pivotal trial success, with strong efficacy numbers and a clear regulatory path, typically moves biotech stocks sharply.
Market effects
Strengthens the bradykinin‑targeted therapy segment and may boost peer biotech valuations.
European biotech investors could see increased appetite for late‑stage oral therapies.
Positive data may influence global HAE treatment landscape and FDA expectations.
Counterpoint
If regulatory scrutiny intensifies or safety concerns emerge, the rally could be short‑lived.
Key entities
- companyPharvaris N.V.
Late‑stage biopharma developing oral HAE therapies.
- analyst_firmWedbush
Reaffirmed Outperform rating with $42 price target.